Journal article
Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series
Journal of pediatric hematology/oncology, Vol.43(3), pp.e431-e435
04/01/2021
DOI: 10.1097/MPH.0000000000001810
PMID: 32341259
Abstract
Thrombopoietin receptor agonists are emerging as a therapeutic option for patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS). We report our experience of treating children with AA/MDS with romiplostim, thrombopoietin receptor agonist.
Three children (AA, 2; MDS, 1) received romiplostim treatment at a median dose of 10 μg/kg/week (starting dose: 5 μg/kg/wk; 2.5 μg/kg/wk increment). Trilineage hematopoietic recovery occurred at a median of 13 weeks (range: 13 to 16 wk) without adverse events. Hematopoiesis continued to improve after therapy discontinuation (median follow-up: 2.8 y; range: 0.5 to 3.0).
Our experience supports the short-term safety and efficacy of romiplostim in children with AA/MDS.
Details
- Title: Subtitle
- Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series
- Creators
- Ahmad Al-Huniti - Stead Family Department of PediatricsNityam Rathi - University of PittsburghArun Modi - Stead Family Department of Pediatrics.Sharathkumar Bhagavathi - University of IowaRoxane Mitten - Stead Family Department of Pediatrics.Anjali A Sharathkumar - Stead Family Department of Pediatrics.
- Resource Type
- Journal article
- Publication Details
- Journal of pediatric hematology/oncology, Vol.43(3), pp.e431-e435
- DOI
- 10.1097/MPH.0000000000001810
- PMID
- 32341259
- ISSN
- 1077-4114
- eISSN
- 1536-3678
- Language
- English
- Date published
- 04/01/2021
- Academic Unit
- Stead Family Department of Pediatrics; Pathology; Hematology/Oncology
- Record Identifier
- 9984185272302771
Metrics
12 Record Views